#267 Serology, Serology: How Accurate and Prevalent Art Thou?
CLINICAL QUESTION
What is the role of serology testing in the COVID-19 pandemic?
BOTTOM LINE
IgM and IgG antibodies may reveal an individual's recent (after ~2 weeks) exposure to COVID-19. How long serology remains positive and whether antibodies confer immunity to subsequent infection is unknown. Many different tests exist, each with different accuracy. Current evidence does not support routine use of serology testing in COVID-19 management.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
Time to antibody seroconversion (after symptom onset):
- 85 hospitalized COVID-19 patients had 216 serial tests.1
- Sharp increase in positivity for IgM and IgG at ~2 weeks.
- IgM 90% positive at day 19, IgG >90% at ~1 month.
- 173 hospitalized COVID-19 patients had 535 serial tests.2
- Median time to seroconversion: IgM=12 days, IgG=14 days.
- Less than 7 days of illness: IgM ~40%.
- Limitations: short studies, unknown length of time IgG remains positive.
- Sampling of 865 people from Los Angeles, 35 antibody tests positive (~4%).3
- 4.7% after adjusting for sex, ethnicity, and income.
- Black patients, those from households with low incomes, and symptomatic patients more likely to test positive.
- If results extrapolated to Canada,4 Canada would have 1.5-1.8 million cases.
- Currently have ~100,000.5
- Population based sampling in Geneva found ~10% of citizens antibody positive.6
- Estimate 11.6 seroconverted citizens for every confirmed COVID-19 case.
- Published:
- Sensitivity (truly have COVID-19 and antibody test positive):7,8 36%-99%.
- Depends on the test characteristics and when patient tested.
- Specificity (truly don’t have COVID-19 and antibody test negative):3,7 89%-99.5%.
- Sensitivity (truly have COVID-19 and antibody test positive):7,8 36%-99%.
- Health Canada Approved Tests:9
- Sensitivity after ~14 days of symptoms: 97.4%-100%.
- Specificity range: 98.5%-100%.
- Limitations: Results mostly from test companies’ in-house calculations.
- No studies have determined whether those who have had COVID-19 (as determined by IgG antibodies) have immunity to another COVID-19 infection.
- This will likely be answered in vaccine trials.
- In the US, companies can bypass approval process to market their tests.
- Over 100 companies have marketed tests.10
- The sensitivity of serological testing in elderly or immunocompromised is unknown.11
- Serology should not routinely be used to diagnose acute COVID-19 infection.12
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
no benefit to test for Covid 19
no benefit to testing for Covid 19 to confirm infection.